A new pyrazole ligand, ,-bis(2(1',5,5'-trimethyl-1,1'-[3,3'-bipyrazol]-1-yl)ethyl)propan-1-amine (L) was synthesized and characterized by H-NMR, C-NMR, FT-IR and HRMS. The coordination ability of the ligand has been employed for the construction of a new family of coordination complexes, namely: [CuLCl] (1), [ML(CHOH)(HO)](ClO) (M = Ni (2), Co (3)) and [FeL(NCS)] (4). The series of complexes were characterized using single-crystal X-ray diffraction, HRMS, FT-IR and UV-visible spectroscopy. Moreover, the iron(ii) analogue was investigated by Fe Mössbauer spectroscopy and SQUID magnetometry. Single-crystal X-ray structures of the prepared complexes are debated within the framework of the cooperative effect of the hydrogen bonding network and counter anions on the supramolecular formations observed. Furthermore, within the context of biological activity surveys, these compounds were reviewed against different types of bacteria to validate their efficiency, including both Gram-positive as well as Gram-negative bacteria. Enhanced behaviour towards f. sp. fungi, were detected for 1 and 4.
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with the poorest prognosis among all types of lung cancer. Developing an effective comprehensive strategy remains a key focus. We herein present the first documented case of a 68-year-old man with limited-stage SCLC who has maintained a complete response (CR) for over 30 months to date.
Chloride ions play vital roles in a variety of biological and environmental processes, making their accurate and efficient detection critical for both research and practical applications. In this perspective, we explore the recent advancements in the development of metal complex-based probes for chloride ion detection, with a focus on complexes involving transition and lanthanide metals. These probes offer remarkable selectivity and sensitivity, achieved through diverse mechanisms such as metal coordination, hydrogen bonding, electrostatic interactions, and halogen or chalcogen bonding.
One very unique feature of oxidorhenium(v) complexes is their dual catalytic activity in both reduction of stable oxyanions like perchlorate ClO and nitrate NO as well as epoxidation of olefins. In our ongoing research efforts, we were interested to study how an electron-withdrawing ligand would affect both these catalytic reactions. Hence, we synthesized the novel bidentate dimethyloxazoline-dichlorophenol ligand HL1 and synthesized oxidorhenium(v) complex [ReOCl(L1)] (1).
Department of Respiratory and Critical Care Medicine, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
The STK11 gene mutation is a common genetic alteration in non-small cell lung cancer (NSCLC) and is significantly associated with poor responses to current immunotherapy regimens. Despite its prevalence, there is currently no established standard for front-line treatment in this subtype of NSCLC, underscoring the increasing need for personalized therapeutic strategies. In this report, we present a case of a patient with STK11-mutant NSCLC who was treated with first-line cadonilimab (10mg/kg) in combination with pemetrexed (500mg/m^2) plus carboplatin (AUC=5), resulting in a notable extension of progression-free survival (PFS).
Background: Carboplatin is a human chemotherapeutic agent which is frequently used in dogs for the management of solid tumors. In human patient, its dosage is adjusted carefully, based on the creatinine clearance computation. In dogs however, the pharmacokinetics of carboplatin is poorly known and the dose 300 mg/m2 is based mostly on empirical data.
